ConductScience.org, home

Paper4135597

Characteristics of an established cell line of retinoblastoma.

Reid TW and 7 others. J Natl Cancer Inst, 1974. Cited by 370 papers, by iCite.

Cite this record

ConductScience Library. Characteristics of an established cell line of retinoblastoma. Papers, record 4135597. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4135597

Download JSON
Cell line
Y-7939 papers
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Characteristics of an established cell line of retinoblastoma.
PubMed
Journal
J Natl Cancer Inst
PubMed
Year
1974
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
370
iCite
Relative citation ratio, by iCite
8.33
iCite
Revised in PubMed
2019-05-11
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Reid TWT W
2Albert DMD M
3Rabson ASA S
4Russell PP
5Craft JJ
6Chu EWE W
7Tralka TST S
8Wilcox JLJ L

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cell LineMajor topic
RetinoblastomaMajor topic
Cell Division
Cell Membrane
Child, Preschool
Chromosomes
Culture Techniques
Female
Humans
Inclusion Bodies
Karyotyping
Microscopy, Electron
Microtubules
Oncogenic Viruses
RNA Viruses
RNA-Directed DNA Polymerase
Templates, Genetic

Source PubMed

Download CSV of topics

Cited by106

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 370 citations.

PMIDTitleJournalYearIn PapersSource
41098871High expression of the eukaryotic initiation factors eIF4a and eIF4e in retinoblastoma.Contemp Oncol (Pozn)2025https://conductscience.org/library/papers/41098871PubMed
40170180A review of the 661W cell line as a tool to facilitate treatment development for retinal diseases.Cell Biosci2025https://conductscience.org/library/papers/40170180PubMed
39731391Impact of Race on the Outcomes of Retinoblastoma Treated With Primary Enucleation: A Global Study of 1426 Patients.Clin Exp Ophthalmol2025https://conductscience.org/library/papers/39731391PubMed
39695086In vitro model of retinoblastoma derived tumor and stromal cells for tumor microenvironment (TME) studies.Cell Death Dis2024https://conductscience.org/library/papers/39695086PubMed
39620144Evaluation of mesenchymal stem cells as an in vitro model for inherited retinal diseases.Front Cell Dev Biol2024https://conductscience.org/library/papers/39620144PubMed
39000021Histone Deacetylases in Retinoblastoma.Int J Mol Sci2024https://conductscience.org/library/papers/39000021PubMed
38730608Gastric Inhibitory Polypeptide Receptor (GIPR) Overexpression Reduces the Tumorigenic Potential of Retinoblastoma Cells.Cancers (Basel)2024https://conductscience.org/library/papers/38730608PubMed
38674157Role of Protein Tyrosine Phosphatase Receptor Type E (PTPRE) in Chemoresistant Retinoblastoma.Int J Mol Sci2024https://conductscience.org/library/papers/38674157PubMed
38447574In vivo CRISPR screening directly targeting testicular cells.Cell Genom2024https://conductscience.org/library/papers/38447574PubMed
38217258
New retinoblastoma (RB) drug delivery approaches: anti-tumor effect of atrial natriuretic peptide (ANP)-conjugated hyaluronic-acid-coated gold nanoparticles for intraocular treatment of chemoresistant RB.
Mol Oncol2024https://conductscience.org/library/papers/38217258PubMed
37606819Inhibition of high level E2F in a RB1 proficient MYCN overexpressing chicken retinoblastoma model normalizes neoplastic behaviour.Cell Oncol (Dordr)2024https://conductscience.org/library/papers/37606819PubMed
37340597Translational screening platform to evaluate chemotherapy in combination with focal therapy for retinoblastoma.Cancer Sci2023https://conductscience.org/library/papers/37340597PubMed
36993823Tumor Suppressor Role of INPP4B in Chemoresistant Retinoblastoma.J Oncol2023https://conductscience.org/library/papers/36993823PubMed
36293469ADAM10 and ADAM17-Novel Players in Retinoblastoma Carcinogenesis.Int J Mol Sci2022https://conductscience.org/library/papers/36293469PubMed
36034735Review: New horizons in retinoblastoma treatment: an updated review article.Mol Vis2022https://conductscience.org/library/papers/36034735PubMed
35873807In vitro Model Systems for Studies Into Retinal Neuroprotection.Front Neurosci2022https://conductscience.org/library/papers/35873807PubMed
35654783Induction of autophagy-dependent ferroptosis to eliminate drug-tolerant human retinoblastoma cells.Cell Death Dis2022https://conductscience.org/library/papers/35654783PubMed
35314658Retinoblastoma Cell Growth In Vitro and Tumor Formation In Ovo-Influence of Different Culture Conditions.Methods Protoc2022https://conductscience.org/library/papers/35314658PubMed
34930522In silico-labeled ghost cytometry.Elife2021https://conductscience.org/library/papers/34930522PubMed
34491442T-type calcium channels as therapeutic targets for treating "giant" retinoblastoma cancer cells.Pflugers Arch2021https://conductscience.org/library/papers/34491442PubMed

See all 106 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/4135597

GET https://conductscience.org/api/papers/v1/4135597/cited_by?page=2